Business Standard

Cipla Q3 net up 10% to Rs 801 cr, posts highest ever quarterly sales in US

Revenue up 6% to Rs 5,810 cr; firm expects US FDA audit at Goa unit

Cipla, Cipla logo, Cipla headquarters
Premium

An employee works at the reception area of Cipla at its headquarters in Mumbai. Photo: Reuters

Sohini Das Mumbai
Mumbai-based drug maker Cipla posted a 10 per cent year-on-year rise in net profit to Rs 801 crore for the third quarter of the financial year 2022-23, riding on the back of a six per cent surge in total revenue from operations to Rs 5,810 crore.

Cipla posted an Ebitda of Rs 1,408 crore for the quarter with a resulting Ebitda margin of 24.2 percent.

The firm's stock ended 2.12 per cent down, at Rs 1,039 on the BSE.

Kunal Randeria, analyst with Nuvama Research, said the revenue was due to emerging markets and active pharmaceutical ingredients (API) performance, and Covid-19 contribution to

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Jan 25 2023 | 5:05 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com